- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07605598
Measuring Pelvic Floor Muscle Fitness Before and After Treatment
Quantitative Assessment of Pelvic Floor Muscle Fitness in Myofascial Pelvic Pain Before and After Myofascially-Directed Therapies
This study is being done to better understand and improve treatment for myofascial pelvic pain, a common cause of long-lasting pelvic pain in women. Myofascial pelvic pain is related to tight or dysfunctional pelvic floor muscles and can cause pain as well as bladder, bowel, and sexual problems. Current clinical evaluations mostly rely on physical examination and patient-reported symptoms and do not fully measure how the pelvic floor muscles are functioning.
The purpose of this study is to measure pelvic floor muscle function using a noninvasive imaging method called near-infrared spectroscopy, or NIRS. This method measures changes in muscle blood flow and oxygen levels during muscle contraction and relaxation. The study will examine whether pelvic floor muscle function improves after different treatments and whether these physiologic changes are associated with improvements in pain and symptoms.
The study will enroll 120 adult women who have had pelvic pain for at least three months and have pelvic floor muscle tenderness on examination. Participants will be randomly assigned to one of three groups: education with relaxation exercises, pelvic floor physical therapy focused on myofascial release, or vaginal medication used to help relax pelvic floor muscles.
Participants will take part in four study visits over a six-month period. During these visits, they will complete questionnaires about pain and pelvic symptoms, undergo pelvic floor examinations, and have pelvic floor muscle imaging using the NIRS device while performing brief muscle contractions and relaxations. Some visits will also include collection of blood, urine, and vaginal samples to measure inflammation.
The information gained from this study may help improve the diagnosis and treatment of myofascial pelvic pain by providing objective measures of pelvic floor muscle function and identifying which treatments are most effective for different patients.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
STUDY OVERVIEW This is a prospective, randomized, controlled clinical study designed to objectively measure pelvic floor muscle (PFM) physiology and inflammatory changes in women with myofascial pelvic pain (MPP). The study uses a novel, transvaginal near-infrared spectroscopy (NIRS) system to assess pelvic floor muscle oxygenation, hemodynamics, and recovery during standardized contraction and relaxation tasks. The overarching goal is to improve objective diagnosis, phenotyping, and personalized treatment of MPP.
Scientific Rationale Myofascial pelvic pain is a common contributor to chronic pelvic pain in women and is characterized by pelvic floor muscle hypertonicity, impaired muscle perfusion, local acidosis, and accumulation of inflammatory mediators. These physiologic abnormalities contribute to pain as well as bladder, bowel, and sexual dysfunction. Current clinical evaluation relies largely on subjective examination and patient-reported symptoms, which limits precision in diagnosis and treatment selection.
Preliminary work has demonstrated that pelvic floor NIRS imaging can reliably distinguish women with MPP from asymptomatic controls and can identify physiologic impairments such as reduced muscle oxygenation and delayed recovery following contraction. This study evaluates whether targeted myofascial therapies improve these objective physiologic measures and whether changes in muscle physiology correlate with symptom improvement and inflammatory biomarkers.
STUDY OBJECTIVES
Primary Objective To determine whether pelvic floor muscle fitness, measured using NIRS-derived oxygenation parameters, improves following myofascial-directed treatments in women with MPP.
Secondary Objectives To characterize NIRS-derived physiologic patterns associated with symptom severity and pelvic floor dysfunction.
To assess relationships between NIRS measures and systemic and local inflammatory biomarkers.
To identify physiologic predictors of treatment response using machine-learning-based analytic approaches.
STUDY DESIGN
Design: Prospective, randomized, controlled trial
Sample size: 120 adult women with myofascial pelvic pain
Randomization: 1:1:1 allocation
Treatment arms:
Education and generalized relaxation (control) Myofascially-directed pelvic floor physical therapy Pharmacologic pelvic floor muscle relaxation
Study duration: Six months per participant
Study visits: Baseline, 1-2 weeks, 3 months, and 6 months
Total participant time: Approximately four hours across all visits
STUDY PROCEDURES
Baseline Visit After informed consent, participants complete validated questionnaires assessing pelvic pain, urinary, bowel, sexual function, psychological symptoms, and quality of life. Participants also complete two 24-hour bladder and bowel diaries.
Clinical assessments include urinalysis and post-void residual if not recently documented, standardized pelvic examination with grading of muscle strength and myofascial tenderness, perineometry, surface electromyography, and bulbospongiosus reflex testing. Pelvic floor NIRS imaging is performed transvaginally during a guided 10-minute protocol involving repeated contraction and relaxation exercises, capturing real-time oxygenated and deoxygenated hemoglobin data across multiple circumferential channels.
Biologic specimens, including blood, urine, and vaginal samples, are collected for inflammatory biomarker analysis.
Follow-Up Assessments Participants return at 1-2 weeks, 3 months, and 6 months to repeat symptom questionnaires, bladder and bowel diaries, pelvic floor examination, and NIRS imaging. Participants also complete a patient global impression of improvement assessment at all visits after treatment. Biologic specimen collection is repeated at the early post-treatment visit.
DATA MANAGEMENT AND SAFETY
All study data are collected and managed using secure, HIPAA-compliant electronic data capture systems. Data are de-identified at the time of entry. An independent monitoring process oversees recruitment, protocol adherence, and adverse events. All study procedures are considered minimal risk and consistent with standard gynecologic and pelvic floor physical therapy care.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Keila S Kimura, B.S.
- Numero di telefono: 310-825-8427
- Email: kskimura@mednet.ucla.edu
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- UCLA
-
Contatto:
- Keila S Kimura, B.S.
- Numero di telefono: 310-825-8427
- Email: kskimura@mednet.ucla.edu
-
Contatto:
- A Lenore Ackerman, MD, PhD
- Numero di telefono: 310-794-7700
- Email: aackerman@mednet.ucla.edu
-
Investigatore principale:
- A Lenore Ackerman, MD, PhD
-
Sub-investigatore:
- Michelle Tororsis, MD
-
Sub-investigatore:
- Jeffery Chiang, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
Women over 18 years of age
Pelvic Pain for more than 3 months
Report an average daily pain intensity score of at least 4 on a 0 to 10 scale
Palpable trigger/tender points in internal pelvic floor muscles on standardized myofascial pelvic floor exam
Willing to refrain from new clinical treatment that may affect pain during the study period
Exclusion Criteria
Inability to participate in clinic visits
Prior invasive pelvic procedures for pain (e.g., prior pelvic surgery, sacral neuromodulation, intradetrusor Botox®) in the past 6 months
Active UTI or vaginal infection
Pregnancy or childbirth in the past 12 months, currently planning a pregnancy
Illicit Drug addiction/regular use of controlled substances (including marijuana use in the past 2 weeks or during the study period)
Pelvic floor physical therapy in the past 3 months
Malignancy or other serious medical condition (e.g., poorly controlled diabetes [HgA1c > 8], chronic renal disease [GFR <30], neurologic or rheumatic disease)
Diagnosed with an alternate cause of pelvic pain (e.g., ulcerative interstitial cystitis, vestibulodynia, vulvar dermatoses, dysmenorrhea)
Urinary retention with a PVR >150 mL
Greater than stage 3 pelvic organ prolapse
Indwelling vaginal devices (e.g., pessary, contraceptive ring. Not including Mirena IUD) that cannot be removed for the study
Inability to sign an informed consent, fill out questionnaires, or complete study interviews
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore placebo: Education
Education and Generalized Relaxation.
Patients are educated about myofascial pelvic pain and given a home course of non-specific relaxation exercises administered via a virtual intervention of five 5-10 min videos.
|
Near-infrared spectroscopy (NIRS) is a noninvasive imaging technique used in this study to assess pelvic floor muscle physiology.
The NIRS device uses near-infrared light to measure changes in oxygenated and deoxygenated hemoglobin within the pelvic floor muscles, providing real-time information about muscle blood flow, oxygenation, and recovery during contraction and relaxation.
The device is used transvaginally during a standardized protocol that includes brief, guided pelvic floor muscle contractions and relaxations.
NIRS measurements are used for assessment purposes only and are not intended for diagnosis or treatment.
Altri nomi:
|
|
Comparatore attivo: Pelvic Floor Physical Therapy
Pelvic floor physical therapy with myofascial release will be performed by a designated female physical therapist who is a Board-Certified Clinical Specialist in Women's Health Physical Therapy.
The methods and approaches used will be at the discretion of the therapist, based on an individual assessment of symptoms and detailed pelvic floor assessment.
|
Near-infrared spectroscopy (NIRS) is a noninvasive imaging technique used in this study to assess pelvic floor muscle physiology.
The NIRS device uses near-infrared light to measure changes in oxygenated and deoxygenated hemoglobin within the pelvic floor muscles, providing real-time information about muscle blood flow, oxygenation, and recovery during contraction and relaxation.
The device is used transvaginally during a standardized protocol that includes brief, guided pelvic floor muscle contractions and relaxations.
NIRS measurements are used for assessment purposes only and are not intended for diagnosis or treatment.
Altri nomi:
|
|
Sperimentale: Pharmacological Release
Compounded intravaginal diazepam 0.5% and baclofen 0.4% ointment.
Participants receive a compounded intravaginal ointment containing diazepam (0.5%) and baclofen (0.4%) to promote pelvic floor muscle relaxation.
Medication is initiated nightly and may be titrated up to three times daily based on symptom response and tolerability.
|
Near-infrared spectroscopy (NIRS) is a noninvasive imaging technique used in this study to assess pelvic floor muscle physiology.
The NIRS device uses near-infrared light to measure changes in oxygenated and deoxygenated hemoglobin within the pelvic floor muscles, providing real-time information about muscle blood flow, oxygenation, and recovery during contraction and relaxation.
The device is used transvaginally during a standardized protocol that includes brief, guided pelvic floor muscle contractions and relaxations.
NIRS measurements are used for assessment purposes only and are not intended for diagnosis or treatment.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in pelvic floor muscle oxygenation with treatment
Lasso di tempo: Baseline to 3 months
|
Change from baseline in pelvic floor muscle oxygenation response to standardized contraction, measured using near-infrared spectroscopy (NIRS) after treatment interventions designed to alter pelvic floor muscle fitness
|
Baseline to 3 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in pelvic floor muscle recovery kinetics after pelvic floor therapies
Lasso di tempo: Baseline to 3 months
|
Change from baseline in pelvic floor muscle oxygenation recovery time following contraction, measured using NIRS, with pelvic floor-directed therapies
|
Baseline to 3 months
|
|
Correlation of change in pelvic pain severity with NIRS metrics
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in average pelvic pain intensity measured using a numeric rating scale (0-10) as correlated with metrics of pelvic floor muscle oxygenation
|
Baseline to 3 months and 6 months
|
|
Patient Global Impression of Improvement (PGI-I)
Lasso di tempo: 3 months and 6 months
|
Participant-reported overall improvement in pelvic symptoms using the Patient Global Impression of Improvement (PGI-I) scale after pelvic-floor directed therapies.
The PGI-I is a single-question, patient-reported scale used to measure perceived treatment response compared to a baseline, which is rated on a seven-point scale from 1 (Very much better) to 7 (Very much worse).
|
3 months and 6 months
|
|
Change in inflammatory biomarkers
Lasso di tempo: Baseline to 1-2 weeks after therapy
|
Change from baseline in systemic and local inflammatory biomarkers measured from blood, urine, and vaginal samples after pelvic-floor directed therapies.
This exploratory aim will examine a wide-range of inflammatory mediators in each biological sample, including: EGF, Eotaxin/CCL11, G-CSF, GM-CSF, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IP-10/CXCL10, MCP-1/CCL2, M-CSF, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TNFα, TNFβ/LTA, VEGF-A.
While the primary analysis will examine IL-6, IL-8, and TNF-β levels before and after treatment (measure in pg/mL), as these have been implicated previously in other myofascial pain conditions, the additional biomarkers may serve to provide additional insight into disease pathophysiology.
|
Baseline to 1-2 weeks after therapy
|
|
Change in the Female Genitouruinary Pain Index
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported pelvic floor-related symptoms, including urinary, pain- and health-related quality of life will be measured using the validated female Genitourinary Pain Index (fGUPI) (scored 0-45, with higher numbers indicated worse pain and quality-of-life).
|
Baseline to 3 months and 6 months
|
|
Change in Colorectal Functional Outcome questionnaire (COREFO)
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported pelvic floor-related and bowel symptoms will be measured using the Colorectal Functional Outcome questionnaire (COREFO) (scored 0-100, where 100 indicates the worst possible bowel function)
|
Baseline to 3 months and 6 months
|
|
Change in International Consultation on Incontinence Questionnaire-female Lower Urinary Tract Symptoms (ICIQ-fLUTS)
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported pelvic floor-related and urinary symptoms, will be measured using the International Consultation on Incontinence Questionnaire-female Lower Urinary Tract Symptoms (ICIQ-fLUTS) (scored 0-48, where higher scores indicate more severe urinary symptoms )
|
Baseline to 3 months and 6 months
|
|
Change in Pelvic Floor Distress Index (PFDI-20)
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported pelvic floor-related, urinary, bowel, and pain symptoms will be measured using the validated Pelvic Floor Distress Index (PFDI-20) (scored 0-300, where higher scores indicate more severe symptoms).
|
Baseline to 3 months and 6 months
|
|
Change in Female Sexual Functional Index (FSFI)
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported sexual symptoms will be measured using validated questionnaires:Female Sexual Functional Index (FSFI) (scored 2-36, where higher scores indicate better sexual function)
|
Baseline to 3 months and 6 months
|
|
Change in the Hospital Anxiety and Depression Scale (HADS)
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported anxiety and depression symptoms will be measured using the validated Hospital Anxiety and Depression Scale (HADS) (scored 0-42, with higher scores indicating higher severity symptoms).
|
Baseline to 3 months and 6 months
|
|
Change in the Short Form 12 (SF-12)
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported health-related quality of life will be measured using the validated Short Form 12 (SF-12), which includes the Physical Component Summary (PCS) and Mental Component Summary (MCS), both weighted assessments measured such that 50 is the median score for the population, meaning that scores below 50 suggest below-average perceived health.
|
Baseline to 3 months and 6 months
|
|
Change in Whole Person Health Index (WPHI)
Lasso di tempo: Baseline to 3 months and 6 months
|
Change from baseline in patient-reported overall health, will be measured using the validated Whole Person Health Index (WPHI), which includes 9 items, each of which is measured on a 5-point Likert scale in which higher scores indicate better self-perceived health.
|
Baseline to 3 months and 6 months
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Prediction of treatment response using NIRS metrics
Lasso di tempo: Baseline to 6 months
|
The Near InfraRed Spectroscopic (NIRS) pelvic floor muscle measurements are obtained vaginally during a series of pelvic floor muscle contractions, both short- and long-duration.
Features abstracted from the resulting NIRS waveforms [change in oxygenated hemoglobin (measure in nM) from baseline to during MVC, the sustainable duration of SMVC (sec), and the decrease in the change in oxygenated hemoglobin with MVC over a series of contractions (measured in nM, indicative of muscle fatigue)] will be combined using generalized linear models to create a single, unitless predictive score that will be correlated with treatment responses.
The magnitude of the clinical treatment response will be measured as a decrease in pain scores expressed as a continuous variable using the Numeric Rating Scale (NRS), a validated 11-point, patient-reported tool.
|
Baseline to 6 months
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Bedaiwy MA, Patterson B, Mahajan S. Prevalence of myofascial chronic pelvic pain and the effectiveness of pelvic floor physical therapy. J Reprod Med. 2013 Nov-Dec;58(11-12):504-10.
- Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014 Mar-Apr;17(2):E141-7.
- Meister MR, Sutcliffe S, Ghetti C, Chu CM, Spitznagle T, Warren DK, Lowder JL. Development of a standardized, reproducible screening examination for assessment of pelvic floor myofascial pain. Am J Obstet Gynecol. 2019 Mar;220(3):255.e1-255.e9. doi: 10.1016/j.ajog.2018.11.1106. Epub 2018 Dec 7.
- Stone RH, Abousaud M, Abousaud A, Kobak W. A Systematic Review of Intravaginal Diazepam for the Treatment of Pelvic Floor Hypertonic Disorder. J Clin Pharmacol. 2020 Dec;60 Suppl 2:S110-S120. doi: 10.1002/jcph.1775.
- Ross V, Detterman C, Hallisey A. Myofascial Pelvic Pain: An Overlooked and Treatable Cause of Chronic Pelvic Pain. J Midwifery Womens Health. 2021 Mar;66(2):148-160. doi: 10.1111/jmwh.13224. Epub 2021 Mar 31.
- Kapurubandara SC, Lowes B, Sansom-Daly UM, Deans R, Abbott JA. A systematic review of diagnostic tests to detect pelvic floor myofascial pain. Int Urogynecol J. 2022 Sep;33(9):2379-2389. doi: 10.1007/s00192-022-05258-7. Epub 2022 Jul 7.
- Deegan EG, Stothers L, Macnab AJ. Technical Development of a Transvaginal Probe Using Near Infrared Light to Monitor Pelvic Floor Muscle Hemodynamics Bilaterally. J Endourol. 2017;31(S2):A43.
- Bhambhani Y. Application of near Infrared Spectroscopy in Evaluating Cerebral and Muscle Haemodynamics during Exercise and Sport. Journal of Near Infrared Spectroscopy. 2012;20(1):117-39. doi: 10.1255/jnirs.978.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Spettroscopia nel vicino infrarosso
- dolore pelvico cronico
- Fisioterapia del pavimento pelvico
- Terapia di rilascio miofasciale
- mialgia del pavimento pelvico
- disfunzione muscolare del pavimento pelvico
- myofascial pelvic pain
- pelvic floor hypertonicity
- NIRS imaging
- Pelvic floor muscle oxygenation
- Pelvic floor muscle blood flow
- Pelvic floor muscle fitness
- Pelvic floor relaxation therapy
- Intravaginal diazepam
- Intravaginal baclofen
- Pelvic floor muscle relaxation medication
- Women's pelvic pain
- Noninvasive pelvic floor assessment
- Pelvic floor imaging
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Dolore
- Manifestazioni neurologiche
- Disordini mentali
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie genitali, femmina
- Disfunzione sessuale, fisiologica
- Disfunzioni sessuali, psicologiche
- Malattie vaginali
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Dolore pelvico
- Dolore facciale
- Vaginismo
Altri numeri di identificazione dello studio
- 25-1502
- R61AT013008-01 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .